Share on StockTwits

Omnicell (NASDAQ:OMCL) CFO Robin Gene Seim sold 2,442 shares of the company’s stock on the open market in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $28.21, for a total value of $68,888.82. Following the sale, the chief financial officer now directly owns 77,150 shares of the company’s stock, valued at approximately $2,176,402. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Omnicell (NASDAQ:OMCL) traded down 0.04% during mid-day trading on Friday, hitting $27.83. The stock had a trading volume of 279,884 shares. Omnicell has a one year low of $20.03 and a one year high of $30.33. The stock’s 50-day moving average is $27.51 and its 200-day moving average is $27.20. The company has a market cap of $1.019 billion and a price-to-earnings ratio of 37.72.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 1st. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. The company had revenue of $101.80 million for the quarter, compared to the consensus estimate of $97.49 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. On average, analysts predict that Omnicell will post $1.23 earnings per share for the current fiscal year.

OMCL has been the subject of a number of recent research reports. Analysts at Topeka Capital Markets initiated coverage on shares of Omnicell in a research note on Thursday, June 12th. They set a “buy” rating and a $30.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Omnicell in a research note on Thursday, May 29th. They now have a $28.00 price target on the stock. Finally, analysts at Stephens initiated coverage on shares of Omnicell in a research note on Tuesday, May 20th. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Omnicell currently has an average rating of “Buy” and a consensus price target of $30.71.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.